PECAM-1 IS REQUIRED FOR TRANSENDOTHELIAL MIGRATION OF LEUKOCYTES

被引:973
|
作者
MULLER, WA [1 ]
WEIGL, SA [1 ]
DENG, XH [1 ]
PHILLIPS, DM [1 ]
机构
[1] POPULAT COUNCIL,NEW YORK,NY 10021
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 1993年 / 178卷 / 02期
关键词
D O I
10.1084/jem.178.2.449
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Platelet/endothelial cell adhesion molecule 1 (PECAM-1; CD31) is crucial to the process of leukocyte transmigration through intercellular junctions of vascular endothelial cells. A monoclonal antibody to PECAM, or recombinant soluble PECAM, blocks transendothelial migration of monocytes by 70-90%. Pretreating either the monocytes or the endothelial junctions with antibody blocks transmigration. If the endothelium is first activated by cytokines, anti-PECAM antibody or soluble recombinant PECAM again block transmigration of both monocytes and neutrophils. Anti-PECAM does not block chemotaxis of either cell type. Light and electron microscopy reveal that leukocytes blocked in transmigration remain tightly bound to the apical surface of the endothelial cell, precisely over the intercellular junction. Thus, the process of leukocyte emigration can be dissected into three successive stages: rolling, mediated by the selectin class of adhesion molecules; tight adhesion, mediated by the leukocyte integrins and their endothelial cell counter-receptors; and now transmigration, which, based on these studies, requires PECAM-1.
引用
收藏
页码:449 / 460
页数:12
相关论文
共 50 条
  • [41] Oxidized LDL specifically promotes the initiation of monocyte invasion during transendothelial migration with upregulated PECAM-1 and downregulated VE-cadherin on endothelial junctions
    Hashimoto, Ken
    Kataoka, Noriyuki
    Nakamura, Emi
    Tsujioka, Katsuhiko
    Kajiya, Fumihiko
    ATHEROSCLEROSIS, 2007, 194 (02) : E9 - E17
  • [42] CELLULAR AND MOLECULAR ASPECTS OF PECAM-1
    NEWMAN, PJ
    ALBELDA, SM
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1992, 34 : S9 - S13
  • [43] Shedding of PECAM-1 during HIV infection: a potential role for soluble PECAM-1 in the pathogenesis of NeuroAIDS
    Eugenin, E. A.
    Gamss, R.
    Buckner, C.
    Buono, D.
    Klein, R. S.
    Schoenbaum, E. E.
    Calderon, T. M.
    Berman, J. W.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2006, 79 (03) : 444 - 452
  • [44] PECAM-1: Conflicts of interest in inflammation
    Privratsky, Jamie R.
    Newman, Debra K.
    Newman, Peter J.
    LIFE SCIENCES, 2010, 87 (3-4) : 69 - 82
  • [45] PECAM-1 is a critical mediator of atherosclerosis
    Stevens, Hazel Y.
    Melchior, Benoit
    Bell, Kelly S.
    Yun, Sujin
    Yeh, Jiunn-Chern
    Frangos, John A.
    DISEASE MODELS & MECHANISMS, 2008, 1 (2-3) : 175 - 181
  • [46] Lymphatic endothelium expresses PECAM-1
    Sawa, Y
    Yoshida, S
    Ashikaga, Y
    Kim, T
    Yamaoka, V
    Shiroto, H
    TISSUE & CELL, 1998, 30 (03): : 377 - 382
  • [47] Characterization of the PECAM-1 promoter.
    Gumina, RJ
    Kirschbaum, N
    Piotrowski, K
    Newman, PJ
    BLOOD, 1995, 86 (10) : 1797 - 1797
  • [48] PECAM-1 association with talin.
    Godyna, S
    Duhon, GL
    McLean, NV
    Romer, LH
    MOLECULAR BIOLOGY OF THE CELL, 1997, 8 : 1175 - 1175
  • [49] PECAM-1: a multifaceted regulator of megakaryocytopoiesis
    Wu, Yue
    Welte, Thomas
    Michaud, Michael
    Madri, Joseph A.
    BLOOD, 2007, 110 (03) : 851 - 859
  • [50] PECAM-1, a key player in neuroinflammation
    Kalinowska, A.
    Losy, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (12) : 1284 - 1290